Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Relmada Therapeutics (NASDAQ:RLMD) posted its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09, FiscalAI reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

• NDV-01 remains on track for registrational development: Relmada plans to file the IND by year-end 2026 and begin the Phase III rescue program after clearance, with approximately 80 clinical sites prepared and 60 designated as primary sites.
• Phase II results support NDV-01’s potential: The company reported a 95% complete response rate at any time and a 76% durable complete response rate at 12 months, with favorable safety and tolerability.
• Manufacturing is the key near-term execution risk. Formulation, process development, and analytical work are complete, but Relmada still needs to secure GMP manufacturing capacity, produce batches, and generate sufficient stability data before filing the IND.
• Relmada reported substantial financial runway: Cash, cash equivalents, and short-term investments totaled $217.7 million at quarter-end, which management expects to fund operations through 2029, including completion of the NDV-01 Phase III rescue program.
• The company has not yet finalized the timing or format of additional clinical disclosures; management suggested that six-month data and a larger patient sample may be more meaningful than the previously anticipated three-month results, potentially shifting disclosure into the first half of 2027.

Relmada Therapeutics Trading Down 8.0%

Shares of RLMD stock traded down $0.43 during trading hours on Friday, hitting $4.94. 2,125,013 shares of the company’s stock were exchanged, compared to its average volume of 1,542,462. The company has a market capitalization of $518.16 million, a PE ratio of -5.49 and a beta of 0.46. Relmada Therapeutics has a 12-month low of $0.55 and a 12-month high of $8.00. The business’s 50 day simple moving average is $6.05 and its 200-day simple moving average is $5.93.

Institutional Trading of Relmada Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new position in shares of Relmada Therapeutics in the second quarter worth about $28,000. Goldman Sachs Group Inc. bought a new stake in shares of Relmada Therapeutics in the 1st quarter valued at about $33,000. LMR Partners LLP purchased a new stake in Relmada Therapeutics during the 2nd quarter valued at about $33,000. Schonfeld Strategic Advisors LLC purchased a new stake in Relmada Therapeutics during the 4th quarter valued at about $64,000. Finally, Jane Street Group LLC bought a new position in Relmada Therapeutics during the 2nd quarter worth approximately $69,000. 45.24% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright assumed coverage on Relmada Therapeutics in a research report on Thursday, June 18th. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relmada Therapeutics in a report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.